Background: Though protective levels of neonatal SARS-CoV2 IgG still warrant further studies, maternal antibodies from COVID-19 vaccination may be the key to neonatal protection against COVID-19 related complications. This study aimed to correlate SARS-CoV2 IgG titers of term newborns delivered to fully vaccinated/boosted mothers with the time of dose completion to delivery and the type of COVID-19 vaccine received by the mothers. Methodology: A single center prospective cohort study that utilized CLIA Anti-S-RBD IgG determination in cord blood was done. Kruskal-Wallis and Mann-Whitney U Test were used to determine significant differences between IgG titers from vaccine types and groups as to trimester when COVID-19 dose was completed. Spearman’s rank was used to determine the correlation between IgG levels and interval of dose completion to delivery. Results: All 177 newborns enrolled in the study had reactive results (> 1 AU/ml) regardless of vaccine type received and trimester of maternal vaccination completion. The highest titers recorded per group was 19,340 AU/ml from the booster group and 5,960 AU/ml from the primary series group. The mRNA vaccinated group exhibited higher titers compared to other vaccine types regardless of the trimester completion for both groups. Conclusions A significant difference between IgG levels showed that higher titers were noted in the booster group compared to the primary series group across all trimesters. There was also a significant correlation between titer levels and time of dose completion to delivery with higher titers associated with more recent dose completion for both groups.
Immunoglobulin G ; COVID-19 Vaccines ; Infant, Newborn

BACKGROUND

Dengue is a global health concern, particularly in tropical regions such as the Philippines. In 2019,Cebu City reported the highest number of dengue cases in Central Visayas with 3,290 cases and 20 deaths, an 11.8% increase compared to 20181 . To help predict disease outcomes and provide timely management, a scoring system, the Daily Dengue Severity Score (DDSS)² was utilized.

OBJECTIVE

To determine the clinicodemographic profile of dengue patients, determine the accuracy of the DDSS in assessing disease severity, and determine a cut off score that suggests severe dengue.

METHODS

Patients 1 month to 18 years admitted for dengue at Perpetual Succour Hospital from January 2018 to December 2020 were included. Cases were classified as Dengue without Warning Signs, Dengue with Warning Signs, and Severe Dengue, and scored using the DDSS. Statistical analysis used were Geometric mean and Area Under the Receiver Operating Characteristic (AUROC) curves to analyze the discriminative performance of the DDSS among the different disease severity states.

RESULTS

Out of 327 cases, 34 were classified as Dengue without Warning Signs, 271 Dengue with Warning Signs, and 22 Severe Dengue. The highest mean DDSS was 17.7 ±14.0 at Day -4 among those with Severe Dengue, and the lowest mean DDSS was 1.1 ± 2.0 at Day +3 among those with Dengue without Warning Signs. A cut off point of 10 on Day -1 predicted subsequent Severe Dengue among patients with Dengue with Warning Signs. In 91.39% of cases, there was a significant relationship between the DDSS and dengue classification, and the higher the DDSS, the more severe the disease.

CONCLUSION

Majority of dengue patients were males, aged 8.1 to 9.2 years. DDSS showed 66.67% sensitivity, 92.86% specificity, a positive likelihood ratio of 9.3, and a cutoff of 10 is predictive of severe dengue among patients with dengue with warning signs.

Human ; Dengue ; Scoring Methods ; Research Design ; Patient Monitoring ; Monitoring, Physiologic